Skip to content

Pharminent

cropped-ChatGPT-Image-May-28-2026-10_46_23-PM.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • Regulatory
  • Boan Biotech Submits BLA to FDA for Two Denosumab Biosimilars
  • Regulatory

Boan Biotech Submits BLA to FDA for Two Denosumab Biosimilars

Big Molecule Watch

On May 29, 2026, Boan Biotech announced that it submitted a Biologics License Application (BLA) to the U.S.

Read full story

pharminent June 4, 2026 (Last updated: June 5, 2026)

Big Molecule Watch

On May 29, 2026, Boan Biotech announced that it submitted a Biologics License Application (BLA) to the U.S.

Read full story

Sign up to receive free daily digest

Check your inbox or spam folder to confirm your subscription.

Post navigation

Previous: SCOTUS backs generic firm Hikma in skinny label dispute
Next: Next Post

Related Stories

  • Regulatory

Biogen’s salanersen gains FDA breakthrough therapy designation for SMA

pharminent June 5, 2026
  • Regulatory

FDA taps prior knowledge to expedite cell and gene therapy development

pharminent June 3, 2026
  • Regulatory

AbbVie receives EC approval for Aquipta to treat migraine

pharminent June 3, 2026

You May Have Missed

  • Commercial

Lilly and Novo face off at ADA 2026 as others seek to compete in obesity

pharminent June 5, 2026
  • Market Access

Medicare Advantage in 2026: Enrollment Update and Key Trends

pharminent June 5, 2026
  • Policy / Pricing

The next FDA commissioner must be a champion for gene therapies

pharminent June 5, 2026
  • Clinical Data

Otsuka energizes IgA neuropathy space with new Phase 3 Voyxact data

pharminent June 5, 2026
Copyright © 2026 All rights reserved. | ReviewNews by AF themes.